DCTH Earnings Prediction
The chart below shows how DCTH performed 10 days before and after its earnings report, based on data from the past quarters. Typically, DCTH sees a -3.07% change in stock price 10 days leading up to the earnings, and a +3.40% change 10 days following the report. On the earnings day itself, the stock moves by +3.68%. This data can give you a slight idea of what to expect for the next quarter's release.
DCTH Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
11.20M
2480.65%
44.22%
Gross Margin
85.36%
23.09%
6.12%
Operating Margin
-11.24%
-99.54%
-77.69%
Net Margin
16.64%
100.36%
-109.40%
EPS
0.06
105.26%
-112.50%
No Data Available
DCTH Earnings Analysis
Delcath Systems Inc Corporation (DCTH.O) Earnings Conference Call
Positive
Quarterly Revenue Surge: 1. Significant Revenue Growth: Delcath Systems reported total revenue of $11.2 million for Q3 2024, including $10 million from HEPZATO, marking a 44% increase over the previous quarter.
Treatment Center Expansion: 2. Strong Center Activation: The company activated 11 treatment centers by the end of Q3 2024, with plans to reach at least 15 by year-end and 30 by the end of 2025, indicating robust expansion in treatment capacity.
Strong Profitability Indicators: 3. High Gross Margins: Delcath achieved gross margins of 85% in Q3 2024, reflecting strong profitability from its product sales.
Improved Disease Control: 4. Positive Clinical Outcomes: Studies presented at ESMO 2024 indicated that HEPZATO provided better disease control and improved progression-free survival compared to traditional therapies for metastatic uveal melanoma.
Cash Reserves and Debt Status: 5. Strong Cash Position: The company ended Q3 2024 with $14 million in cash and no outstanding debt, positioning it well for future growth and clinical trials.
Negative
Treatment Rate Decline: 1. Declining Treatment Rates: The average treatment rate post-activation averaged just under two treatments per month in Q3, with expectations for this rate to remain flat due to the addition of new centers.
Rising Operating Expenses: 2. Increased Operating Expenses: Selling, general, and administrative expenses rose to $7 million in Q3 2024, up from $6.2 million in Q3 2023, primarily due to marketing and personnel costs associated with the commercial launch.
Ongoing Cash Burn: 3. Cash Burn Rate: Despite a revenue increase, cash used in operations was approximately $3.6 million in Q3 2024, indicating ongoing cash burn as the company ramps up its operations.
Holiday Treatment Disruptions: 4. Seasonal Treatment Disruptions: The company anticipates one and a half to two weeks fewer treatment days in Q4 due to the holiday season, which could extend the timeframe between treatments for some patients.
Stable R&D Investment: 5. Flat R&D Spending: Research and development expenses are expected to remain relatively flat in Q4, with full-year R&D costs projected to range from $35 million to $40 million, indicating limited investment in new initiatives in the short term.
DCTH FAQs
How does DCTH typically perform around its earnings report dates?
Is Delcath Systems Inc (DCTH) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
DCTH Earning Call Sentiment
Delcath Systems Inc (DCTH) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
DCTH.O
6.05%Positive
The earnings call highlights strong revenue growth, significant gross margins, and a positive cash position, indicating financial health. The NTAP status and European market expansion are promising. Despite potential regulatory and competitive risks, the optimistic guidance and additional clinical trials suggest future growth. The Q&A section reflects confidence in handling seasonal challenges and financial stability. The exercise of warrants strengthens the financial position further. Overall, these factors point to a positive stock price movement in the near term.